These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9531047)

  • 1. Enhancement of fibrinolysis by plactins: structure-activity relationship and effects in human U937 cells and in mice.
    Inoue T; Hasumi K; Sugimoto M; Endo A
    Thromb Haemost; 1998 Mar; 79(3):591-6. PubMed ID: 9531047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent cyclic peptide inhibitors of VLA-4 (alpha4beta1 integrin)-mediated cell adhesion. Discovery of compounds like cyclo(MePhe-Leu-Asp-Val-D-Arg-D-Arg) (ZD7349) compatible with depot formulation.
    Dutta AS; Gormley JJ; Coath M; Hassall L; Hayward CF; Gellert PR; Kittlety RS; Alcock PJ; Ferguson R; Halterman T; Jamieson A; Moors JA; Moores JM; Rees A; Wood LJ; Reilly CF; Haworth D
    J Pept Sci; 2000 Aug; 6(8):398-412. PubMed ID: 10969869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual modulation of prothrombin activation by the cyclopentapeptide plactin.
    Harada T; Tsuruta T; Yamagata K; Inoue T; Hasumi K
    FEBS J; 2009 May; 276(9):2516-28. PubMed ID: 19476492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cyclopentapeptide plactin enhances cellular binding and autoactivation of the serine protease plasma hyaluronan-binding protein.
    Yamamoto E; Yamamichi S; Choi-Miura NH; Hasumi K
    Thromb Res; 2010 Nov; 126(5):406-13. PubMed ID: 20864147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation of plactins A, B, C and D, novel cyclic pentapeptides that stimulate cellular fibrinolytic activity.
    Inoue T; Hasumi K; Kuniyasu T; Endo A
    J Antibiot (Tokyo); 1996 Jan; 49(1):45-9. PubMed ID: 8609084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alcohol-induced up-regulation of fibrinolytic activity and plasminogen activators in human monocytes.
    Tabengwa EM; Wheeler CG; Yancey DA; Grenett HE; Booyse FM
    Alcohol Clin Exp Res; 2002 Aug; 26(8):1121-7. PubMed ID: 12198385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent cyclic monomeric and dimeric peptide inhibitors of VLA-4 (alpha4beta1 integrin)-mediated cell adhesion based on the Ile-Leu-Asp-Val tetrapeptide.
    Dutta AS; Crowther M; Gormley JJ; Hassall L; Hayward CF; Gellert PR; Kittlety RS; Alcock PJ; Jamieson A; Moores JM; Rees A; Wood LJ; Reilly CF; Haworth D
    J Pept Sci; 2000 Jul; 6(7):321-41. PubMed ID: 10946997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Syntheses of low-hemolytic antimicrobial gratisin peptides.
    Tamaki M; Kokuno M; Sasaki I; Suzuki Y; Iwama M; Saegusa K; Kikuchi Y; Shindo M; Kimura M; Uchida Y
    Bioorg Med Chem Lett; 2009 May; 19(10):2856-9. PubMed ID: 19369073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of fibrinolytic activity of U937 cells by malformin A1.
    Koizumi Y; Hasumi K
    J Antibiot (Tokyo); 2002 Jan; 55(1):78-82. PubMed ID: 11918070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity relationship of cyclic pentapeptide malformins as fibrinolysis enhancers.
    Koizumi Y; Nagai K; Hasumi K; Kuba K; Sugiyama T
    Bioorg Med Chem Lett; 2016 Nov; 26(21):5267-5271. PubMed ID: 27680590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.
    Erchegyi J; Waser B; Schaer JC; Cescato R; Brazeau JF; Rivier J; Reubi JC
    J Med Chem; 2003 Dec; 46(26):5597-605. PubMed ID: 14667214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
    Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
    Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformational change of ascidiacyclamide caused by asymmetric modification for an isoleucine residue: structural analyses of [Gly], [Leu], and [Phe]ascidiacyclamides by x-ray diffraction and NMR spectroscopy.
    Doi M; Shinozaki F; In Y; Ishida T; Yamamoto D; Kamigauchi M; Sugiura M; Hamada Y; Kohda K; Shioiri T
    Biopolymers; 1999 May; 49(6):459-69. PubMed ID: 10193193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cyclic pentapeptide derived from the second EGF-like domain of Factor VII is an inhibitor of tissue factor dependent coagulation and thrombus formation.
    Orning L; Fischer PM; Hu CK; Agner E; Engebretsen M; Husbyn M; Petersen LB; Orvim U; Llinas M; Sakariassen KS
    Thromb Haemost; 2002 Jan; 87(1):13-21. PubMed ID: 11848442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of fibrinolytic activity of bovine aortic endothelial cells by ginsenoside Rb2.
    Liu JW; Wei DZ; Du CB; Zhong JJ
    Acta Pharmacol Sin; 2003 Feb; 24(2):102-8. PubMed ID: 12546716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimalarial activity of cyclolinopeptide A and its analogues.
    Bell A; McSteen PM; Cebrat M; Picur B; Siemion IZ
    Acta Pol Pharm; 2000 Nov; 57 Suppl():134-6. PubMed ID: 11293244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of plasminogen binding to U937 cells and fibrin by complestatin.
    Tachikawa K; Hasumi K; Endo A
    Thromb Haemost; 1997 Jan; 77(1):137-42. PubMed ID: 9031464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of the isomers of cyclo(Trp-Pro) on heart and ion-channel activity.
    Jamie H; Kilian G; Dyason K; Milne PJ
    J Pharm Pharmacol; 2002 Dec; 54(12):1659-65. PubMed ID: 12542896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
    Cheng LL; Stoev S; Manning M; Derick S; Pena A; Mimoun MB; Guillon G
    J Med Chem; 2004 Apr; 47(9):2375-88. PubMed ID: 15084136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic peptide derived from alpha-fetoprotein inhibits growth of human breast cancer: investigation of the pharmacophore and synthesis optimization.
    DeFreest LA; Mesfin FB; Joseph L; McLeod DJ; Stallmer A; Reddy S; Balulad SS; Jacobson HI; Andersen TT; Bennett JA
    J Pept Res; 2004 May; 63(5):409-19. PubMed ID: 15140158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.